Technology area: Biotechnology & Pharmaceuticals
17 pending office actions • 7 art units • 15 examiners • 0 of 17 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Actinium Pharmaceuticals Inc. currently manages 17 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 15 distinct examiners and 7 distinct art units. The presence of these 17 pending office actions shows the current volume of activity for this entity. Practitioners should note the distribution across the 7 distinct art units, which involves different examination environments. The coordination of responses across different technical centers is a key consideration for the legal team.
SAMALA, JAGADISHWAR RAO is the busiest examiner for this portfolio, currently overseeing 2 pending office actions. While the company workload involves 15 distinct examiners, this specific official is responsible for 2 matters. This distribution suggests that the innovations are being evaluated by different groups within the Biotechnology & Pharmaceuticals field. Having 15 distinct examiners involved means that the prosecution strategy must account for the individual tendencies of various officials. Each examiner may bring a different perspective to the claims, requiring a specific approach for every individual case file.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (24%) |
| Double-patenting only | 1 (6%) |
| Double-patenting + other | 3 (18%) |
| Multi-statute (no §101) | 9 (53%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAMALA, JAGADISHWAR RAO | 2 | 67.9% | +55.7% |
| VU, JAKE MINH | 2 | 41.0% | +27.0% |
| WARD, PAUL V | 1 | 83.2% | -12.2% |
| CRAIG, KAILA ANGELIQUE | 1 | 33.8% | +25.2% |
| DICKINSON, PAUL W | 1 | 63.2% | +9.6% |
| SKOKO III, JOHN JOSEPH | 1 | 53.0% | +55.2% |
| BAEK, JONGHWAN NMN | 1 | 50.0% | +0.0% |
| SCHLIENTZ, LEAH H | 1 | 41.8% | +38.7% |
| DONOHUE, SEAN R | 1 | 41.4% | +21.0% |
| ROGERS, JAMES WILLIAM | 1 | 46.1% | +22.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18901169 | METHOD FOR TREATING CANCER USING A BCL-2 INHIBITOR IN CONJUNCTION WITH AN ALPHA-EMITTING RADIOIMMUNOTHERAPEUTIC | WARD, PAUL V | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16755590 | ANTI-CD45-BASED LYMPHODEPLETION METHODS AND USES THEREOF IN CONJUNCTION WITH ACT-BASED CANCER THERAPIES | JOHANSEN, PETER N. | 30d overdue |
| 16754400 | METHODS FOR CANCER TREATMENT USING A RADIOLABELED ANTI-CD45 IMMUNOGLOBULIN AND ADOPTIVE CELL THERAPIES | BUTTICE, AUDREY L | 33d |
| 18696453 | RADIOIMMUNOCONJUGATES TARGETING GRP78 FOR USE IN THE TREATMENT OF CANCER | DICKINSON, PAUL W | — |
| 18684103 | RADIOIMMUNOCONJUGATES TARGETING CALRETICULIN FOR USE IN THE TREATMENT OF CANCER | SAMALA, JAGADISHWAR RAO | — |
| 18036723 | METHODS FOR TREATING CANCER USING COMBINATIONS OF EPIGENETIC THERAPIES AND RADIOCONJUGATE TARGETING AGENTS | SCHLIENTZ, LEAH H | — |
| 18685667 | RADIOIMMUNOCONJUGATES TARGETING PHOSPHATIDYLSERINE FOR USE IN THE TREATMENT OF CANCER | VU, JAKE MINH | — |
| 17726296 | COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER | ROGERS, JAMES WILLIAM | — |
| 17606226 | COMPOSITIONS AND METHODS OF IMMUNODEPLETION FOR THE TREATMENT OF MALIGNANT AND NON-MALIGNANT HEMATOLOGICAL DISEASES | WESTERBERG, NISSA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16627872 | TREATMENTS FOR A HEMATOLOGICAL MALIGNANCY | SAMALA, JAGADISHWAR RAO | 58d overdue |
| 18044356 | METHOD FOR TREATING ACUTE MYELOID LEUKEMIA USING VENETOCLAX IN CONJUNCTION WITH LINTUZUMAB-AC225 | DONOHUE, SEAN R | 11d overdue |
| 18887845 | METHODS FOR TREATING CANCER USING COMBINATIONS OF PARP INHIBITORS AND ANTIBODY RADIOCONJUGATES | CRAIG, KAILA ANGELIQUE | — |
| 18684103 | RADIOIMMUNOCONJUGATES TARGETING CALRETICULIN FOR USE IN THE TREATMENT OF CANCER | SAMALA, JAGADISHWAR RAO | — |
| 18557988 | RADIOIMMUNOCONJUGATES DIRECTED TO NKG2D LIGANDS FOR THE TREATMENT OF CANCER | SKOKO III, JOHN JOSEPH | — |
| 18036723 | METHODS FOR TREATING CANCER USING COMBINATIONS OF EPIGENETIC THERAPIES AND RADIOCONJUGATE TARGETING AGENTS | SCHLIENTZ, LEAH H | — |
| 18685667 | RADIOIMMUNOCONJUGATES TARGETING PHOSPHATIDYLSERINE FOR USE IN THE TREATMENT OF CANCER | VU, JAKE MINH | — |
| 17726296 | COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER | ROGERS, JAMES WILLIAM | — |
| Art Unit | Apps |
|---|---|
| 1618 | 11 |
| 1622 | 1 |
| 1643 | 1 |
| 1614 | 1 |
| 1646 | 1 |
| 1644 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18901169 | METHOD FOR TREATING CANCER USING A BCL-2 INHIBITOR IN CONJUNCTION WITH AN ALPHA-EMITTING RADIOIMMUNOTHERAPEUTIC | WARD, PAUL V | 1622 | DP | Non-Final OA | — | Pending | Sep 30, 2024 |
| 18887845 | METHODS FOR TREATING CANCER USING COMBINATIONS OF PARP INHIBITORS AND ANTIBODY RADIOCONJUGATES | CRAIG, KAILA ANGELIQUE | 1618 | §103 | Non-Final OA | — | Pending | Sep 17, 2024 |
| 18696453 | RADIOIMMUNOCONJUGATES TARGETING GRP78 FOR USE IN THE TREATMENT OF CANCER | DICKINSON, PAUL W | 1618 | §102§112 | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18684103 | RADIOIMMUNOCONJUGATES TARGETING CALRETICULIN FOR USE IN THE TREATMENT OF CANCER | SAMALA, JAGADISHWAR RAO | 1618 | §102§103 | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18557988 | RADIOIMMUNOCONJUGATES DIRECTED TO NKG2D LIGANDS FOR THE TREATMENT OF CANCER | SKOKO III, JOHN JOSEPH | 1643 | §102§103§112DP | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18553757 | RADIOIMMUNOTHERAPY DIRECTED TO CCR8 FOR DEPLETION OF TUMOR INFILTRATING REGULATORY T CELLS | BAEK, JONGHWAN NMN | 1618 | §103DP | Non-Final OA | — | Pending | Oct 03, 2023 |
| 18036723 | METHODS FOR TREATING CANCER USING COMBINATIONS OF EPIGENETIC THERAPIES AND RADIOCONJUGATE TARGETING AGENTS | SCHLIENTZ, LEAH H | 1618 | §102§103 | Non-Final OA | — | Pending | May 12, 2023 |
| 18044356 | METHOD FOR TREATING ACUTE MYELOID LEUKEMIA USING VENETOCLAX IN CONJUNCTION WITH LINTUZUMAB-AC225 | DONOHUE, SEAN R | 1618 | §103 | Final Rejection | 11d overdue | Pending | Mar 07, 2023 |
| 18685667 | RADIOIMMUNOCONJUGATES TARGETING PHOSPHATIDYLSERINE FOR USE IN THE TREATMENT OF CANCER | VU, JAKE MINH | 1618 | §103§112 | Final Rejection | — | Pending | Mar 02, 2023 |
| 17726296 | COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER | ROGERS, JAMES WILLIAM | 1618 | §103§112 | Non-Final OA | — | Pending | Apr 21, 2022 |
| 17725544 | COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER | CABRAL, ROBERT S | 1614 | §103§112DP | Non-Final OA | — | Pending | Apr 20, 2022 |
| 17702648 | COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER | CUNNINGCHEN, KATHLEEN MARY | 1646 | §103 | Final Rejection | 35d overdue | Pending | Mar 23, 2022 |
| 17606226 | COMPOSITIONS AND METHODS OF IMMUNODEPLETION FOR THE TREATMENT OF MALIGNANT AND NON-MALIGNANT HEMATOLOGICAL DISEASES | WESTERBERG, NISSA M | 1618 | §103§112 | Non-Final OA | — | Pending | Oct 25, 2021 |
| 17293663 | COMBINATION OF RADIOIMMUNOTHERAPY AND IMMUNE CHECKPOINT THERAPY IN THE TREATMENT OF CANCER | VU, JAKE MINH | 1618 | §102§103§112Other | Non-Final OA | — | Pending | May 13, 2021 |
| 16755590 | ANTI-CD45-BASED LYMPHODEPLETION METHODS AND USES THEREOF IN CONJUNCTION WITH ACT-BASED CANCER THERAPIES | JOHANSEN, PETER N. | 1644 | §103§112 | Non-Final OA | 30d overdue | Pending | Apr 12, 2020 |
| 16754400 | METHODS FOR CANCER TREATMENT USING A RADIOLABELED ANTI-CD45 IMMUNOGLOBULIN AND ADOPTIVE CELL THERAPIES | BUTTICE, AUDREY L | 1647 | §103§112 | Final Rejection | 33d | Pending | Apr 08, 2020 |
| 16627872 | TREATMENTS FOR A HEMATOLOGICAL MALIGNANCY | SAMALA, JAGADISHWAR RAO | 1618 | §103 | Final Rejection | 58d overdue | Pending | Dec 31, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialActinium Pharmaceuticals Inc. has 17 pending office actions as of October 2026, spread across 7 art units and 15 examiners.
Jagadishwar Rao Samala has the most, with 2 of Actinium Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
